SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001176256-13-000165
Filing Date
2013-03-15
Accepted
2013-03-15 10:36:46
Documents
8
Period of Report
2012-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2012 nymoxpharma20f121231.htm 20-F 1071634
2 COMMON STOCK PRIVATE PURCHASE AGREEMENT DATED NOVEMBER 1, 2012 exhibit4-v.htm EX-4.V 87472
3 SOX SECTION 302 CEO CERTIFICATION exhibit12-a.htm EX-12.A 5450
4 SOX SECTION 302 CFO CERTIFICATION exhibit12-b.htm EX-12.B 5398
5 SOX SECTION 906 CEO CERTIFICATION exhibit13-a.htm EX-13.A 1650
6 SOX SECTION 906 CFO CERTIFICATION exhibit13-b.htm EX-13.B 1606
7 nymoxpharma20f121231x45x1.jpg GRAPHIC 6920
8 nymoxpharma20f121231x47x1.jpg GRAPHIC 3313
  Complete submission text file 0001176256-13-000165.txt   1188656
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 5143323222
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 13692601
SIC: 2835 In Vitro & In Vivo Diagnostic Substances